Chevy Chase Trust Holdings LLC Has $63.41 Million Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Chevy Chase Trust Holdings LLC boosted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 9.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 486,195 shares of the life sciences company’s stock after purchasing an additional 42,053 shares during the quarter. Chevy Chase Trust Holdings LLC owned 0.31% of Illumina worth $63,405,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Cinctive Capital Management LP boosted its position in shares of Illumina by 188.7% during the third quarter. Cinctive Capital Management LP now owns 129,510 shares of the life sciences company’s stock worth $16,889,000 after purchasing an additional 84,655 shares in the last quarter. Concentric Capital Strategies LP acquired a new stake in Illumina during the 3rd quarter worth $13,369,000. Arohi Asset Management PTE Ltd. bought a new position in Illumina during the third quarter worth about $8,242,000. Bamco Inc. NY grew its stake in Illumina by 14.7% in the third quarter. Bamco Inc. NY now owns 383,621 shares of the life sciences company’s stock valued at $50,028,000 after acquiring an additional 49,214 shares during the period. Finally, Erste Asset Management GmbH bought a new stake in shares of Illumina in the third quarter worth about $7,538,000. Institutional investors own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on ILMN shares. UBS Group boosted their price objective on Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Scotiabank reduced their price target on shares of Illumina from $176.00 to $164.00 and set a “sector outperform” rating for the company in a report on Thursday, August 15th. Stephens raised their price objective on shares of Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a report on Tuesday, November 12th. Hsbc Global Res raised shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 target price for the company in a research note on Thursday, October 17th. Finally, Royal Bank of Canada increased their target price on Illumina from $252.00 to $254.00 and gave the stock an “outperform” rating in a report on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $164.00.

Illumina Stock Performance

Shares of ILMN stock opened at $144.15 on Monday. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The company has a fifty day moving average price of $141.88 and a two-hundred day moving average price of $126.03. The stock has a market cap of $22.86 billion, a P/E ratio of -14.47 and a beta of 1.13. Illumina, Inc. has a one year low of $99.23 and a one year high of $156.66.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The firm had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.08 billion. During the same quarter in the previous year, the business earned $0.33 earnings per share. The business’s revenue was down 3.5% compared to the same quarter last year. As a group, equities analysts predict that Illumina, Inc. will post 4.11 EPS for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.